PHARMACEUTICAL RESEARCH, vol.36, no.7, 2019 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus
bendamustine, ibrutinib, modeling, pharmacokinetics, rituximab, CHRONIC LYMPHOCYTIC-LEUKEMIA, MULTICENTER PHASE-II, TARGET, BENDAMUSTINE, ASSOCIATION, ELIMINATION, CLEARANCE, BTK
Dokuz Eylül University Affiliated:
Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab.